Oct 12, 2021 8:00am EDT Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program
Oct 04, 2021 8:00am EDT Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
Sep 13, 2021 4:05pm EDT Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021
Jul 29, 2021 8:00am EDT Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101
Jul 15, 2021 8:00am EDT Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
May 27, 2021 4:30pm EDT Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
May 18, 2021 4:05pm EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
Apr 06, 2021 4:05pm EDT Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 04, 2021 8:30am EST Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley
